Carna Biosciences, Inc. (4572) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Peptidream, Inc.

Cyfuse Biomedical KK

MEDINET Co., Ltd.

Oncolys BioPharma, Inc.

StemCell Institute

OncoTherapy Science, Inc.

Carna Biosciences, Inc.

Chiome Bioscience, Inc.

SUSMED, Inc.

GNI Group Ltd.

Stella Pharma Corp.

Why is Carna Biosciences, Inc. ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -48.27% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -358.28

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 21.12%, its profits have fallen by -2.9%

Underperformed the market in the last 1 year

The stock has generated a return of 21.12% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 69.64%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Carna Biosciences, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Carna Biosciences, Inc.

13.21%

20.96

93.15%

Japan Nikkei 225

69.64%

2.62

26.55%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-12.57%

EBIT Growth (5y)

-48.27%

EBIT to Interest (avg)

-358.28

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.77

Sales to Capital Employed (avg)

0.40

Tax Ratio

0.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

22.66

EV to EBIT

-3.46

EV to EBITDA

-3.46

EV to Capital Employed

14.65

EV to Sales

12.41

PEG Ratio

Dividend Yield

ROCE (Latest)

-422.96%

ROE (Latest)

-694.24%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -2.71% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -438.18 %

INVENTORY TURNOVER RATIO(HY)

Highest at 1.26 times

NET SALES(Q)

Highest at JPY 183.63 MM

OPERATING PROFIT(Q)

Highest at JPY -458.44 MM

OPERATING PROFIT MARGIN(Q)

Highest at -249.64 %

PRE-TAX PROFIT(Q)

Highest at JPY -488.97 MM

NET PROFIT(Q)

Highest at JPY -490.09 MM

-12What is not working for the Company

INTEREST(HY)

At JPY 30.39 MM has Grown at 2,885.07%

ROCE(HY)

Lowest at -243.87%

CASH AND EQV(HY)

Lowest at JPY 2,000.27 MM

DEBTORS TURNOVER RATIO(HY)

Lowest at 6.17 times

Here's what is working for Carna Biosciences, Inc.

Net Sales

At JPY 183.63 MM has Grown at 26.85%

over average net sales of the previous four periods of JPY 144.76 MM

MOJO Watch

Near term sales trend is very positive

Net Sales (JPY MM)

Net Sales

Highest at JPY 183.63 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Operating Profit

Highest at JPY -458.44 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (JPY MM)

Operating Profit Margin

Highest at -249.64 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at JPY -488.97 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Net Profit

Highest at JPY -490.09 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

Debt-Equity Ratio

Lowest at -438.18 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio

Highest at 1.26 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -2.71% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Carna Biosciences, Inc.

Interest

At JPY 30.39 MM has Grown at 2,885.07%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv

Lowest at JPY 2,000.27 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio

Lowest at 6.17 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio